A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer
Status:
Terminated
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3, multicenter, randomized, double-blind, placebo controlled study of
Rilotumumab (AMG 102) with Cisplatin and Capecitabine (CX) for untreated advanced mesenchymal
epithelial transition factor (MET)-positive gastric or gastroesophageal junction
adenocarcinoma (GEJ).